HBRM Herborium Group Inc (PK)

Herborium Group, Inc., (PINKSHEETS: HBRM) www.herborium.com, a Botanical Therapeutics™ company, today announced it has satisfied OTC® Market requirements and now qualifies as a company with Current Information -- the highest tier attainable on OTC Markets.

Herborium, develops, licenses and markets proprietary, all natural botanically based medicines (Botanical Therapeutics®) in the high demand sectors of dermatology, women and men's health, and wellness.

AcnEase®, the Company's flagship product, is a proprietary, systemically acting Botanical Therapeutic targeting acne and rosacea in both females and males of all ages. There are over 60 million individuals suffering from acne and 17 million of those with symptoms of rosacea. AcnEase® has been clinically tested and proven safe and effective to treat both teens and adults with acne. (www.acnease.com).

With Roche Pharmaceuticals Accutane -- the only other systemic treatment for acne, removed from the market due to a class action suit naming a number of Accutane's serious adverse side effects -- AcnEase® is the only all botanical, safe and clinically tested systemic acne treatment on the market.

"I am pleased our regulatory compliance initiative has successfully elevated Herborium's OTC Markets tier status to Current Information," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. We intend to continue our regulatory compliance initiatives including a return on the Bulletin Board (BB). This latest achievement marks the most recent milestone in Herborium's continuing efforts to build investors' confidence and assert the Company's global presence.

"We expect this filing validation to foster investors' confidence in our corporate strategy and their interest in our present and upcoming initiatives leading to the Company's growth, and to reinforcing our position in the growing Natural Health Market," Olszewski concluded.

About Herborium Group, Inc. Herborium Group, Inc., a Botanical Therapeutics® company, focused on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For More Information please inquire: Herborium Group, Inc. DrAgnes@Herborium.com